• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Castle Biosciences, Inc. - Common stock (NQ:CSTL)

16.80 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 23, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 16.80
Bid (Size) 16.41 (5)
Ask (Size) 17.47 (1)
Prev. Close 16.80
Today's Range 16.80 - 16.80
52wk Range 15.45 - 35.84
Shares Outstanding 25,167,365
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
FDA Grants Breakthrough Device Designation to Castle Biosciences’ DecisionDx®-Melanoma Test
July 23, 2025
From Castle Biosciences, Inc.
Via GlobeNewswire
Castle Biosciences Honored with Multiple Top Workplaces Awards Recognizing the Company’s Strong Culture
July 17, 2025
Castle earns recognition as a national Healthcare Industry Top Workplace, an Arizona Top Workplace and receives five Top Workplaces Culture Excellence awards 
From Castle Biosciences, Inc.
Via GlobeNewswire

Performance

YTD
-40.1%
-40.1%
1 Month
-10.9%
-10.9%
3 Month
-21.0%
-21.0%
6 Month
-36.9%
-36.9%
1 Year
-17.2%
-17.2%

More News

Read More
Castle Biosciences to Release Second Quarter 2025 Financial Results and Host Conference Call on Monday, Aug. 4, 2025
July 14, 2025
From Castle Biosciences, Inc.
Via GlobeNewswire
Earnings Scheduled For May 5, 2025
May 05, 2025
Via Benzinga
Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 19, 2025
From Castle Biosciences, Inc.
Via GlobeNewswire
Castle Biosciences Enters Collaboration and License Agreement with SciBase to Develop Diagnostic Tests for Dermatologic Diseases
June 16, 2025
From Castle Biosciences, Inc.
Via GlobeNewswire
Castle Biosciences’ Chief Executive Officer Derek Maetzold to Participate in Panel Discussion During the 2025 BIO International Convention
June 11, 2025
From Castle Biosciences, Inc.
Via GlobeNewswire
Castle Biosciences’ Founder, President and CEO Derek Maetzold Honored with Prestigious Lifetime Achievement Award by The American Business Awards®
June 04, 2025
From Castle Biosciences, Inc.
Via GlobeNewswire
New Data at ASCO 2025 Affirms DecisionDx®-Melanoma's Ability to Improve Upon Staging-Based Risk Stratification and Predict Survival Outcomes
May 29, 2025
From Castle Biosciences, Inc.
Via GlobeNewswire
Castle Biosciences to Present at the 2025 Jefferies Global Healthcare Conference
May 21, 2025
From Castle Biosciences, Inc.
Via GlobeNewswire
Real-World Study Confirms Long-Term Performance of DecisionDx®-UM for Metastatic Risk Stratification in Uveal Melanoma and Utility of PRAME Biomarker for Refining Risk When Considered with the DecisionDx-UM Class Result
May 09, 2025
From Castle Biosciences, Inc.
Via GlobeNewswire
Castle Biosciences Celebrates Skin Cancer Awareness Month
May 07, 2025
From Castle Biosciences, Inc.
Via GlobeNewswire
Nike To $70? Here Are 10 Top Analyst Forecasts For Tuesday
May 06, 2025
Via Benzinga
Ichor Holdings Posts Weak Earnings, Joins Fabrinet, Vertex Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
May 06, 2025
Via Benzinga
Castle Biosciences Reports First Quarter 2025 Results
May 05, 2025
From Castle Biosciences, Inc.
Via GlobeNewswire
Castle Biosciences to Acquire Previse
May 05, 2025
From Castle Biosciences, Inc.
Via GlobeNewswire
New Data at DDW 2025 Further Demonstrates the TissueCypher® Test's Ability to Identify Patients at Increased Risk for Developing Esophageal Cancer
May 02, 2025
From Castle Biosciences, Inc.
Via GlobeNewswire
New Study Shows Castle Biosciences’ DecisionDx®-Melanoma Test Outperforms Staging and CP-GEP in Identifying Patients at Low Risk of Sentinel Lymph Node Positivity
April 30, 2025
From Castle Biosciences, Inc.
Via GlobeNewswire
DecisionDx®-Melanoma Test Ordered More Than 200,000 Times for Patients Diagnosed with Cutaneous Melanoma
April 28, 2025
From Castle Biosciences, Inc.
Via GlobeNewswire
New Data at AACR Annual Meeting Highlights Use of DecisionDx®-Melanoma to Identify Early-Stage Melanoma Patients at High Risk of Distant Metastasis
April 25, 2025
From Castle Biosciences, Inc.
Via GlobeNewswire
Castle Biosciences to Release First Quarter 2025 Financial Results and Host Conference Call on Monday, May 5, 2025
April 14, 2025
From Castle Biosciences, Inc.
Via GlobeNewswire
Castle Biosciences Strengthens Commitment to Esophageal Cancer Awareness Through Collaborative Partnerships
April 08, 2025
From Castle Biosciences, Inc.
Via GlobeNewswire
Castle Biosciences Honored with a Top Workplaces USA Award for Fourth Consecutive Year
April 07, 2025
From Castle Biosciences, Inc.
Via GlobeNewswire
Publication of Data from Prospective, Multicenter Study Demonstrates Positive Survival Outcomes in Patients with Low-Risk Melanoma Who Avoided Sentinel Lymph Node Biopsy with Information from Castle Biosciences’ DecisionDx®-Melanoma Test
April 03, 2025
From Castle Biosciences, Inc.
Via GlobeNewswire
Castle Biosciences to Present New Data at EADO Supporting the Clinical Value of the DecisionDx®-Melanoma Test in Guiding Risk-Aligned Management of Patients with Melanoma
April 01, 2025
From Castle Biosciences, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Castle Biosciences, Inc. - Common stock publicly traded?
Yes, Castle Biosciences, Inc. - Common stock is publicly traded.
What exchange does Castle Biosciences, Inc. - Common stock trade on?
Castle Biosciences, Inc. - Common stock trades on the Nasdaq Stock Market
What is the ticker symbol for Castle Biosciences, Inc. - Common stock?
The ticker symbol for Castle Biosciences, Inc. - Common stock is CSTL on the Nasdaq Stock Market
What is the current price of Castle Biosciences, Inc. - Common stock?
The current price of Castle Biosciences, Inc. - Common stock is 16.80
When was Castle Biosciences, Inc. - Common stock last traded?
The last trade of Castle Biosciences, Inc. - Common stock was at 07/23/25 04:00 PM ET
What is the market capitalization of Castle Biosciences, Inc. - Common stock?
The market capitalization of Castle Biosciences, Inc. - Common stock is 422.81M
How many shares of Castle Biosciences, Inc. - Common stock are outstanding?
Castle Biosciences, Inc. - Common stock has 423M shares outstanding.
Site Logo
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap